Glaucoma is a disease defined as optic nerve damage. The primary cause of this nerve damage is elevated pressure inside the eye (intraocular pressure). Damage to the optic nerve can lead to progressive sight loss over the course of a patient’s life, among other glaucoma symptoms.
Over the past several decades in the United States, the use of surgery as a stand-alone procedure for glaucoma treatment has declined steadily. This is due to the fact that the medications (eyedrops) available to treat the disease have improved dramatically, while standard surgical treatment for glaucoma are still considered to be high-risk for sight-threatening complications. The risks associated with some glaucoma treatment surgeries, such as aqueous shunts or trabeculectomies, are often unacceptably high when compared to the risks associated with medical treatment.
MIGS or Micro-Invasive Glaucoma Surgery, is great news for glaucoma treatment patients who are considering cataract surgery. One such microstent, roughly the size of an eyelash, can be placed into the eye’s drainage system during cataract surgery. It acts as a kind of scaffolding that helps to open and enlarge the drainage system. In so doing, the stent helps to lower intraocular pressure. This innovative device is similar in form and fashion to the stents used for heart conditions such as coronary artery disease.
Because insertion of the device is done at the same time as cataract surgery, patients who need or want cataract surgery can have a combined cataract and glaucoma treatment procedure. The cataract portion is performed to improve vision, and the microstent placement is performed to help control glaucoma. Insertion of the microstent generally adds only a few minutes to the surgery and is done when the cataract portion is completed. The microstent adds little overall risk to the procedure. Insertion of the microstent, however, can help greatly with the task of controlling eye pressure and thus controlling a patient’s glaucoma.
Most patients with both cataracts and glaucoma are considered to be good candidates for this combined procedure. The microstent provides patients with an opportunity to reduce the number of medications they use to manage their disease. It also provides the opportunity to improve eye pressure without being subjected to an ever-increasing number of topical medications (eyedrops), each of which can have side effects for both their eyes and other organs such as the heart and lungs.
We are fortunate at Barnet Dulaney Perkins Eye Center to have Dr. Neil Atodaria, a board-certified, fellowship-trained glaucoma expert who specializes in the management of cataracts in patients who also suffer from glaucoma. He has been performing surgical treatment for glaucoma for nearly a decade in Arizona. He is proficient in other glaucoma surgeries as well, and is on the cutting edge of improving existing procedures.
Dr. Atodaria and our other physicians and staff members will be happy to provide information to any patient who is interested in this surgical option. For those not interested in the microstent, other combined procedures are available. For example, Dr. Atodaria can perform a laser procedure at the time of cataract surgery known as endocyclophotocoagulation (ECP). This procedure has been paired successfully with cataract surgery for nearly two decades and has been shown to be very effective.
Please ask your doctor or one of our scheduling team members for more information on combined cataract and glaucoma surgery. This option is available at our practices throughout the state, including Phoenix, Tucson and Flagstaff.